Kamada Ltd.
KMDA
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunizatioā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.35
Price+0.69%
$0.05
1Y
Price
Market Cap
$422.662m
Small
Price/Earnings 3y Avg5y Avg
23x
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$166.640m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
$16.061m
-
1y CAGR-
3y CAGR-
5y CAGREPS
$0.29
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$251.957m
$375.105m
Assets$123.148m
Liabilities$11.098m
DebtDebt to Assets
3.0%
0.3x
Debt to EBITDAFree Cash Flow
$36.279m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company